Update on MDS therapy: from famine to feast

Area of Science:

• Hematology
• Oncology
• Stem Cell Biology

Background:

• Myelodysplastic syndromes (MDS) are acquired hematopoietic stem cell disorders.
• Characterized by ineffective hematopoiesis, cellular dysfunction, and a high risk of transformation into acute myeloid leukemia (AML).
• Disease progression and patient outcomes are influenced by prognostic factors, but current models have limitations.

Purpose of the Study:

• To review the evolving landscape of myelodysplastic syndromes (MDS) treatment.
• To highlight the availability of new FDA-approved therapies.
• To provide a timely overview of current therapeutic options for MDS.

Main Methods:

• Literature review of recent advancements in MDS treatment.
• Analysis of current prognostic factors and their impact.
• Examination of newly approved therapeutic agents and their efficacy.

Main Results:

• The treatment paradigm for MDS has shifted from primarily supportive care to include a growing arsenal of targeted therapies.
• Several new FDA-approved therapies are now available, significantly expanding treatment options.
• The natural history of MDS remains variable, underscoring the need for personalized treatment approaches.

Conclusions:

• The treatment landscape for MDS is rapidly evolving with the introduction of novel therapies.
• Current prognostic models, while useful, are imperfect, necessitating ongoing research and treatment individualization.
• The availability of multiple FDA-approved therapies marks a significant advancement in managing MDS and warrants a comprehensive review.